You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

COVID-19: Baystate Responds with Resilience and Innovation

October 11, 2020
The Innovator Fall 2020 COVID edition

The COVID-19 pandemic is having a profound impact on healthcare systems worldwide. Baystate’s clinicians, researchers, faculty, innovators, and community partners are stepping up to meet these challenges.

Disruption is Often the Source of Innovation

The Innovator's Fall 2020 edition focuses on the many ways Baystate Health has responded with resilience and innovation:
  • Convalescent plasma for COVID-19 therapy
  • Partnering with industry to develop swabs
  • Breast cancer research adjusts to COVID-19
  • Harnessing technology to support telework and clinical care
  • COVACTA trial of tocilizumab, a treatment for COVID-19 related pneumonia
  • Creating a research registry of patients hospitalized with COVID-19
  • Sourcing PPE: face shield development with UMass Amherst
  • Novel Urine Marker May Reduce Dialysis-Requiring Kidney Injury in COVID-19
  • Scaling up lab testing and supply chain capacity
  • Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease (ORCHID) Trial
  • Rapid development and adoption of a respiratory protocol to decrease intubation in COVID-19

 > Read the Special COVID Edition of The Innovator